What are the effects of two separate vaccinations?

 

What are the effects of two separate vaccinations?

The study found that people who took two doses of Estrazenica had a stronger immune response if given a third, booster dose of another vaccine.

What if the two vaccines used to prevent a global pandemic were different, and what would be the impact on coronary immunity and protection? Research in the UK claims that it will improve the body's immune system.

In this regard, a study conducted in the UK has shown that different corona vaccines give better immunity to the body. According to the details, a study has shown that different types of vaccines have better immunity, the results of the study said that giving two doses to Pfizer and AstraZeneca, and three doses of AstraZeneca are better. Better resistance

According to media reports, the trials showed that people who took two doses of AstraZeneca had a stronger immune response, if given a booster dose of a third, second vaccine. It was said. According to the report, the Pfizer and Moderna vaccines provide long-term immunity against Corona and more antibodies are produced when Pfizer and another dose of AstraZeneca is given.

It should be noted that some countries are already using mixed doses, including Spain and Germany, where these young people are given Pfizer and modern mRNA vaccines as a second dose, which is the first dose. But I have taken AstraZeneca. These countries have started using mixed food after blood clotting cases came to light.

 Johnson & Johnson, on the other hand, says its only diet code 19 vaccines has been effective against the highly contagious delta strain of corona and that the immune response lasts for at least eight months.

The company released 2 research reports.

What are the effects of two separate vaccinations?

One study included eight people who had been vaccinated against the Johnson and Johnson code.

Research has shown that the immune system cells and antibodies in their blood effectively neutralize the corona-type delta, which is the most common in India.

The second study was based on 20 vaccine users.

Both research reports were not published in any medical journal but on the pre-print server BioArchive.

"We believe our vaccine provides long-lasting protection against code 19 and increases the level of activity that deactivates the delta," said Paul Stifles, Johnson & Johnson's chief scientific officer.

Matthias Momin, head of research and development at Johnson & Johnson's Johnson subsidiary, said the data came from an eight-month study that showed a single dose of the vaccine had a strong antibody response. It grows over time instead of decreasing.

Earlier, Johnson and Johnson released the results of a third phase trial of the vaccine in late January, which found that they were 66% effective in preventing mild to severe illness, but The company said. That its effectiveness against the severe disease was 85%.

The vaccine was 72 percent effective against mild to severe disease in the United States, 66 percent in Latin America, and 57 percent in South Africa, the company said.

For the first time, however, data have been released on its effectiveness against Delta species

UAE unique award
Biotech Pfizer Corona Vaccine Production Increases